DeepMed Research

Foresee Pharmaceuticals Co., Ltd.

🇹🇼Taiwan

Country: 🇹🇼Taiwan

Ownership: Public

Established: 2013-01-01

Employees: 51

Market Cap: -

Website: http://www.foreseepharma.com

Clinical Trials

Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer

Phase 3

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: FP-014

First Posted Date: 2025-01-27

Last Posted Date: 2025-04-27

Lead Sponsor: Foresee Pharmaceuticals Co., Ltd.

Target Recruit Count: 148

Registration Number: NCT06795178

Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer

Phase 3

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Triptorelin Mesylate

First Posted Date: 2025-01-27

Last Posted Date: 2025-04-27

Lead Sponsor: Foresee Pharmaceuticals Co., Ltd.

Target Recruit Count: 148

Registration Number: NCT06795191

Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD

Phase 2

Recruiting

Conditions: Group 3 Pulmonary Hypertension

Interventions: Drug: Mirivadelgat
Drug: placebo

First Posted Date: 2024-06-26

Last Posted Date: 2025-05-02

Lead Sponsor: Foresee Pharmaceuticals Co., Ltd.

Target Recruit Count: 126

Registration Number: NCT06475781

Locations: 🇨🇳
Taipei Veterans General Hospital, Taipei City, Taiwan
🇨🇳
Hualien Tzu Chi Hospital, Hualien City, Taiwan
🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan

and more 6 locations

Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: FP-020
Other: placebo

First Posted Date: 2024-03-27

Last Posted Date: 2024-11-13

Lead Sponsor: Foresee Pharmaceuticals Co., Ltd.

Target Recruit Count: 64

Registration Number: NCT06334211

Locations: 🇦🇺
Scientia Clinical Research Ltd, Randwick, New South Wales, Australia

Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

Phase 3

Recruiting

Conditions: Puberty; Precocious, Central

Interventions: Drug: Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide

First Posted Date: 2022-08-09

Last Posted Date: 2025-05-18

Lead Sponsor: Foresee Pharmaceuticals Co., Ltd.

Target Recruit Count: 93

Registration Number: NCT05493709

Locations: 🇺🇸
Arizona University, Tucson, Arizona, United States
🇺🇸
Rady Children's Hospital- San Diego, San Diego, California, United States
🇺🇸
Nemours Children's Health Center, Jacksonville, Florida, United States

and more 40 locations

A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

Phase 2

Terminated

Conditions: Severe to Critical COVID 19 With Associated ARDS

Interventions: Drug: FP-025 100 mg
Drug: FP-025 300 mg
Drug: Placebo

First Posted Date: 2021-02-11

Last Posted Date: 2024-01-05

Lead Sponsor: Foresee Pharmaceuticals Co., Ltd.

Target Recruit Count: 90

Registration Number: NCT04750278

Locations: 🇺🇸
Velocity San Diego, La Mesa, California, United States
🇺🇸
Velocity Chula Vista, Chula Vista, California, United States
🇺🇸
Trinity Health Center, Minto, North Dakota, United States

and more 5 locations

A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia

Phase 1

Withdrawn

Conditions: Fanconi Anemia

Interventions: Drug: FP-045

First Posted Date: 2020-08-21

Last Posted Date: 2025-03-06

Lead Sponsor: Foresee Pharmaceuticals Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT04522375

Locations: 🇺🇸
Lucille Packard Children's Hospital, Stanford University, Palo Alto, California, United States
🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States

The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.

Phase 2

Completed

Conditions: Asthma, COPD

Interventions: Drug: FP-025 capsules
Drug: Placebo FP-025 capsules

First Posted Date: 2019-03-01

Last Posted Date: 2024-05-30

Lead Sponsor: Foresee Pharmaceuticals Co., Ltd.

Target Recruit Count: 27

Registration Number: NCT03858686

Locations: 🇳🇱
Academic Medical Centre/University of Amsterdam, Department of Respiratory Medicine and Experiment Immunology, Amsterdam, Netherlands
🇳🇱
QPS Netherlands - Clinical Pharmacology Unit, Groningen, Netherlands

Multiple-Dose, Dose-Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of FP-045

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Cohort 1 - FP-045 oral solution
Drug: Placebo (for FP-045 oral solution)
Drug: Cohort 2 - FP-045 oral solution
Drug: Cohort 3 - FP-045 oral solution

First Posted Date: 2018-09-27

Last Posted Date: 2022-04-29

Lead Sponsor: Foresee Pharmaceuticals Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT03686930

Locations: 🇦🇺
Nucleus Networks, Melbourne, Australia

A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: FP-025 (MMP-12 inhibitor)

First Posted Date: 2017-10-09

Last Posted Date: 2018-08-13

Lead Sponsor: Foresee Pharmaceuticals Co., Ltd.

Target Recruit Count: 32

Registration Number: NCT03304964

Locations: 🇳🇱
QPS Netherlands B.V., Petrus Campersingel 123, Groningen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy